Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cipla
Daiichi Sankyo
Argus Health
Farmers Insurance
McKinsey

Generated: July 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,193,732

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,193,732
Title:Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo- [2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
Inventor(s): Calienni; John Vincent (Cranford, NJ), Chen; Guang-Pei (Livingston, NJ), Gong; Baoqing (Morris Plains, NJ), Kapa; Prasad Koteswara (Parsippany, NJ), Saxena; Vishal (Quincy, MA)
Assignee: Novartis AG (Basel, CH) Astex Therapeutics, LTD (Cambridge, GB)
Application Number:13/882,353
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,193,732
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,193,732

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate TABLET, TABLET;ORAL 209935-001 May 4, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp KISQALI ribociclib succinate TABLET;ORAL 209092-001 Mar 13, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,193,732

PCT Information
PCT FiledNovember 09, 2011PCT Application Number:PCT/US2011/059890
PCT Publication Date:May 18, 2012PCT Publication Number: WO2012/064805

International Family Members for US Patent 9,193,732

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083797 ➤ Try a Free Trial
Australia 2011326620 ➤ Try a Free Trial
Australia 2016203534 ➤ Try a Free Trial
Australia 2017221805 ➤ Try a Free Trial
Australia 2018274883 ➤ Try a Free Trial
Brazil 112013010167 ➤ Try a Free Trial
Canada 2815839 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
AstraZeneca
Chubb
Boehringer Ingelheim
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.